Global analysis on the mutations associated with multidrug-resistant urogenital mycoplasmas and ureaplasmas infection: a systematic review and meta-analysis

• Published in: Annals of clinical microbiology and antimicrobials Vol. 22; no. 1; p. 70
• Main Authors: Abavisani, Mohammad, Keikha, Masoud
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.08.2023; BioMed Central; BMC
• Subjects: Antibiotic resistance; Antibiotics; Antimicrobial agents; Confidence intervals; Control; Drug resistance; Drug resistance in microorganisms; Fluoroquinolones; Genetic testing; HIV; Human immunodeficiency virus; Identification and classification; Infections; Infertility; Inflammatory diseases; Meta-analysis; Multidrug resistance; Multidrug resistant organisms; Mutation; Mycoplasma infections; Mycoplasmatales; Pathogens; Pelvic inflammatory disease; Pneumonia; Prevention; Protein synthesis; Public health; Sexually transmitted diseases; Software; Statistical analysis; STD; Tetracyclines; Ureaplasma; Ureaplasma infections; Iran; Mycoplasma infections; Mutation; Ureaplasma infections; Drug resistance
• ISSN: 1476-0711; 1476-0711
• DOI: 10.1186/s12941-023-00627-6

The emergence of multidrug-resistant (MDR) strains of genital pathogens, notably Mycoplasma genitalium and Ureaplasma spp., constitutes a significant global threat today. The present study aimed to evaluate the prevalence and trend of changes in MDR mycoplasma and ureaplasma strains. An exhaustive search was performed across the ISI Web of Science, PubMed, Scopus, ScienceDirect, and Google Scholar databases to accumulate relevant studies without restrictions until April 2023. We used event rate and corresponding 95% confidence intervals to determine the frequency of resistance-related mutations and examine the trend of antibiotic resistance changes. The data from 27 studies, including 24,662 patients across 14 countries, were evaluated. Out of the total studies, 20 focused on M. genitalium infections, and five on Ureaplasma spp. The frequency of resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones in clinical strains of M. genitalium was 43.5%, 13.1%, and 18.6%, respectively. The prevalence of M. genitalium strains with double resistance and MDR was 11.0% and 17.4%, respectively. The incidence of both double-drug-resistant and MDR strains was higher in the World Health Organization (WHO) Western Pacific Region than in European and American populations. For Ureaplasma strains, resistance-associated mutations to macrolides, tetracyclines, and fluoroquinolones were 40.8%, 25.7%, and 90.3%, respectively. The rate of antibiotic resistance was higher in the African population compared to the European and WHO Western Pacific Regions. The rate of MDR Ureaplasma infections was 13.2%, with a higher incidence in the African population compared to the WHO Western Pacific and European regions. The proliferation and spread of MDR Mycoplasma and Ureaplasma strains present a significant public health challenge. The situation is indeed alarming, and the rising trend of MDR M. genitalium and MDR Ureaplasma infections suggests that therapies involving macrolides and fluoroquinolones may become less effective.